Clene prices $4 million registered direct offering with insider participation
Clene said the September 15, 2026 raise, backed by its chairman, CEO and other existing holders, is expected to fund operations into mid-first quarter 2027.
SEC filing
Latest
3 stories
Wednesday, September 16
Clene sells $4 million in stock directly to insiders and existing holders
The Nasdaq-listed biotech priced 1,219,513 shares at $3.28 apiece in a direct offering, with directors and officers committing about $2.1 million as the company flags going-concern doubt.
SEC filing
Friday, August 14
Clene reports Q2 2026 results, plans ALS drug filing for early Q4
Clene said it plans to submit an accelerated approval application for CNM-Au8 in ALS in early fourth quarter 2026, citing new survival data tied to a nerve-damage biomarker.
SEC filing